Tonsillectomy, Appendectomy Linked to Increased MS Risk
Brain Imaging in Multiple Sclerosis
What Risks Are MS Patients Willing to Take for Improvement?
TYSABRI: JCV Test Stratifies PML Risk in Antibody-Positive MS
ANOTHER NEW MS DRUG: Siponimod for Relapsing-Remitting MS
Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis
Natalizumab inhibits the expression of human endogenous retroviruses of theW family in multiple sclerosis patients: a longitudinal cohort study
Tumefactive multiple sclerosis lesions under fingolimod treatment
Therapeutic Decision Making in a New Drug Era in Multiple Sclerosis
Alemtuzumab (Lemtrada) Gets Positive Opinion supporting marketing authorization for the treatment of relapsing-remitting multiple sclerosis.
Ophthalmologic Manifestations of Multiple Sclerosis
JCV Test 'Useful But Not Sufficient' to Gauge PML Risk
Brain Imaging in Multiple Sclerosis
What Risks Are MS Patients Willing to Take for Improvement?
TYSABRI: JCV Test Stratifies PML Risk in Antibody-Positive MS
ANOTHER NEW MS DRUG: Siponimod for Relapsing-Remitting MS
Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis
Natalizumab inhibits the expression of human endogenous retroviruses of theW family in multiple sclerosis patients: a longitudinal cohort study
Tumefactive multiple sclerosis lesions under fingolimod treatment
Therapeutic Decision Making in a New Drug Era in Multiple Sclerosis
Alemtuzumab (Lemtrada) Gets Positive Opinion supporting marketing authorization for the treatment of relapsing-remitting multiple sclerosis.
Ophthalmologic Manifestations of Multiple Sclerosis
JCV Test 'Useful But Not Sufficient' to Gauge PML Risk
